epilepsy

News

Angelini has agreed to buy Catalyst Pharma for up to $4.1bn, its first acquisition since 2021, which would mark its entry into the US market.

News

UCB has dipped its toe into the M&A waters once again with an agreement to buy US biotech Neurona and its cell therapy for a common form of epilepsy.

News

Praxis looks like it could be filing for approval of two products next year, after its childhood epilepsy drug delivered a win in a pivotal trial.

News

An AI-powered wearable device that warns people with epilepsy about an impending seizure will launch in Europe next year.

News

Angelini Pharma has licensed a preclinical-stage mTOR inhibitor from South Korean biotech Sovargen with potential for genetic forms of epilepsy.

R&D

Epilepsy affects women differently than men, owing to the complexity of brain health and the historical lack of investment in women’s health.